RE:RE:Thank youI will be more than happy to see such multipliers.
Just to correct - So far AGN is running 2 clinical trials
1) COVID - https://clinicaltrials.gov/ct2/show/NCT04382924?term=algernon&draw=2&rank=1
2) IPF & its assoicated cough - https://clinicaltrials.gov/ct2/show/NCT04318704?term=algernon&draw=2&rank=2
AGN has NO clinical trial for chronic cough alone as an indication. But fixing cough in IPF patients will be a multi billion $$ feast. No companies have shown any relief in cough in IPF patients. These patients cough 200-250 times a day (which is 2-3x than normal chronic cough patients).
Merck Gefapixant (which is in Ph3-registrational for chronic cough and could be a block buster drug) failed to show relief in IPF related cough.
IPF cough is the worst thing to fix coz many patients lung injury is so severe that in many cases they are missing part of their lung. Like I said some physician prescribe them Ninetadinib or Perfenidone for IPF cough.
But the moment AGN initiates a trial in CHronic cough or NASH then valuation will be even harder to perform.